CANCER:

Giant Cell Tumor of Bone

No biomarker No biomarker	Giant Cell Tumor of Bone Giant Cell Tumor of Bone	No biomarker No biomarker	Giant Cell Tumor of Bone Giant Cell Tumor of Bone	denosumab Sensitive: A1 - Approval	denosumab Sensitive: A1 - Approval
No biomarker No biomarker	Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor	No biomarker No biomarker	Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval	pexidartinib Sensitive: A1 - Approval
No biomarker No biomarker	Chordoma Chordoma	No biomarker No biomarker	Chordoma Chordoma	sorafenib Sensitive: A2 - Guideline	sorafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	No biomarker No biomarker	Chordoma Chordoma	dasatinib Sensitive: A2 - Guideline	dasatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	No biomarker No biomarker	Chordoma Chordoma	YD312 Sensitive: A2 - Guideline	YD312 Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	No biomarker No biomarker	Chordoma Chordoma	sunitinib Sensitive: A2 - Guideline	sunitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	No biomarker No biomarker	Chordoma Chordoma	erlotinib Sensitive: A2 - Guideline	erlotinib Sensitive: A2 - Guideline
TMB-H TMB-H	Chordoma Chordoma	TMB-H TMB-H	Chordoma Chordoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
EGFR expression EGFR expression	Chordoma Chordoma	EGFR expression EGFR expression	Chordoma Chordoma	lapatinib Sensitive: A2 - Guideline	lapatinib Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Chordoma Chordoma	MSI-H/dMMR MSI-H/dMMR	Chordoma Chordoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Chordoma Chordoma	No biomarker No biomarker	Chordoma Chordoma	imatinib Sensitive: A2 - Guideline	imatinib Sensitive: A2 - Guideline
SMARCB1 negative SMARCB1 negative	Chordoma Chordoma	SMARCB1 negative SMARCB1 negative	Chordoma Chordoma	tazemetostat Sensitive: C2 – Inclusion Criteria	tazemetostat Sensitive: C2 – Inclusion Criteria
PIK3CA amplification PIK3CA amplification	Chordoma Chordoma	PIK3CA amplification PIK3CA amplification	Chordoma Chordoma	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
PIK3CA M1043I PIK3CA M1043I	Chordoma Chordoma	PIK3CA M1043I PIK3CA M1043I	Chordoma Chordoma	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
PTEN deletion PTEN deletion	Chordoma Chordoma	PTEN deletion PTEN deletion	Chordoma Chordoma	PDGFR inhibitor Resistant: C4 – Case Studies	PDGFR inhibitor Resistant: C4 – Case Studies
PTEN deletion PTEN deletion	Chordoma Chordoma	PTEN deletion PTEN deletion	Chordoma Chordoma	PDGFR inhibitor + HDAC inhibitor Sensitive: C4 – Case Studies	PDGFR inhibitor + HDAC inhibitor Sensitive: C4 – Case Studies
H3F3A mutation + ARID2 mutation H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone Giant Cell Tumor of Bone	H3F3A mutation + ARID2 mutation H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone Giant Cell Tumor of Bone	denosumab Resistant: C4 – Case Studies	denosumab Resistant: C4 – Case Studies
COL6A3-CSF1 fusion COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor	COL6A3-CSF1 fusion COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor	gefitinib + mitoxantrone Sensitive: C4 – Case Studies	gefitinib + mitoxantrone Sensitive: C4 – Case Studies
AXL underexpression AXL underexpression	Chordoma Chordoma	AXL underexpression AXL underexpression	Chordoma Chordoma	afatinib Sensitive: D – Preclinical	afatinib Sensitive: D – Preclinical
STK33 underexpression STK33 underexpression	Chordoma Chordoma	STK33 underexpression STK33 underexpression	Chordoma Chordoma	afatinib Sensitive: D – Preclinical	afatinib Sensitive: D – Preclinical

Giant Cell Tumor of Bone

Associations(20)

Associations
(20)